Digene DNA Pap Test Cost-Benefit Studies Set Stage For Reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Recent studies evaluating the cost-effectiveness of Digene's DNA Pap test for cervical cancer may help support reimbursement for a primary screening indication pending FDA approval, the firm says